Before taking Dacomitinib(Vizimpro)

Patients should avoid proton pump inhibitors and use caution with CYP2D6 substrates while on VIZIMPRO.

Important Safety Information

VIZIMPRO can cause fetal harm, so effective contraception is advised for females of reproductive potential. It is also not recommended during breastfeeding. Concomitant use with proton pump inhibitors should be avoided due to reduced efficacy. Additionally, caution is needed when taking other drugs that are CYP2D6 substrates.

Dacomitinib(Vizimpro)
​A kinase inhibitor indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have specific EGFR mutations.
RELATED ARTICLES
Precautions for Dacomitinib

It is of great importance for both patients and doctors to understand the precautions before using dacomitinib...

Monday, September 8th, 2025, 17:01
Medication Precautions for Dacomitinib

Dacomitinib is a targeted drug for non-small cell lung cancer (NSCLC) with positive EGFR mutations. Its medical...

Monday, September 8th, 2025, 14:12
/ 1
2 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved